General Information


We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. This receptor, CD6, plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.

Employees: 7
Founded: 2017
Contact Information
Address 2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037, US
Phone Number 858-412-5302
Web Address http://www.equilliumbio.com
View Prospectus: Equillium
Financial Information
Market Cap $234.5mil
Revenues $0 mil (last 12 months)
Net Income $-4.4 mil (last 12 months)
IPO Profile
Symbol EQ
Exchange NASDAQ
Shares (millions): 4.7
Price range $14.00 - $14.00
Est. $ Volume $65.4 mil
Manager / Joint Managers Jefferies/ Leerink Partners/ Stifel
CO-Managers -
Expected To Trade: 10/12/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change